6 reports

OF THESE, ##% OF PATIENTS EXPERIENCE A CHRONIC CONDITION AND ##% OF THESE REQUIRE OPIOIDS FOR PAIN RELIEF.

  • Clinical Trial
  • Ovarian Cancer
  • United States
  • Forecast
  • Nektar Therapeutics

Also additional data showed rapid and sustained pain relief from as early as week ##, which was sustained out to ## years in PsA patients.

  • Clinical Trial
  • Oncology
  • Ovarian Cancer
  • United States
  • GlobalData's company
  • PAIN, FIVE PATIENTS EXPERIENCED IMPROVEMENT IN PAIN AT WEEK SIX OR WEEK 12 PER INVESTIGATOR REPORT.

In this cohort of patients, the adverse events were headache, diarrhoea, anemia, fatigue, arthralgia (joint pain) and back pain.

  • Hospital
  • Monoclonal Antibody
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases.

  • Hospital
  • Monoclonal Antibody
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

None were unexpected and only one (abdominal pain) was classified as possibly-related to Cvac.

  • Hospital
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.